EUVIMEDEUVIMED entdecken
Crossref

The Impact of Prelung Transplant HLA Antibodies on Post-transplant Outcomes in Recipients With Autoimmune Lung Disease

Benjamin Grobman, Joshua M Diamond, Hilary J Goldberg, Andrew M Courtwright

Transplantation Proceedings · 2024

DOI: 10.1016/j.transproceed.2024.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Benjamin Grobman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Lung Transplantation, HLA Antigens, Autoimmune Diseases. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Patients with advanced lung disease who have HLA antibodies against potential donors have reduced opportunities for transplant. Not all HLA antibodies, however, have the same impact on post-transplant outcomes. It is unknown whether HLA antibodies arising in the context of autoimmune lung disease are associated with increased antibody mediated rejection (AMR) or bronchiolitis obliterans stage 1 (BOS1)-free survival. METHODS: This study used retrospective data from SRTR to examine BOS1-free survival and AMR among sensitized recipients with autoimmune ILD compared to sensitization recipients with nonautoimmune ILD, accounting for other sources of sensitization such as pregnancy and blood transfusions. This study did not use organs from prisoners and participants were neither coerced nor paid. RESULTS: Sensitized recipients with autoimmune ILD did not have differences in BOS1-free survival when adjusting for sensitizing exposures (HR = 0.90, 95% CI: 0.70-1.16) or clinical covariates (HR = 0.96, 95% CI: 0.83-1.12). There was also no difference in AMR (OR = 1.92, 95% CI: 1.04-3.52). CONCLUSIONS: HLA antibodies arising in the context of autoimmune ILD do not appear to have a differential impact on BOS1-free survival or AMR. This provides further evidence that patients sensitized via autoimmune lung diseases do not require separate decision-making regarding HLA antibody status compared to the overall sensitized population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationHLA AntigensAutoimmune DiseasesHumansRetrospective StudiesFemaleMiddle AgedMaleGraft RejectionTreatment OutcomeLung DiseasesBronchiolitis ObliteransAdultAged

Substanzen

HLA Antigens

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts.
  • Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Division of Pulmonary and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: andrew.courtwright@pennmedicine.upenn.edu.

Zitieren

APA

Grobman, B., Diamond, J. M., Goldberg, H. J., & Courtwright, A. M. (2024). The Impact of Prelung Transplant HLA Antibodies on Post-transplant Outcomes in Recipients With Autoimmune Lung Disease. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.06.006

Vancouver

Grobman B, Diamond JM, Goldberg HJ, Courtwright AM. The Impact of Prelung Transplant HLA Antibodies on Post-transplant Outcomes in Recipients With Autoimmune Lung Disease. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.06.006

BibTeX
@article{Grobman2024,
  author = {Grobman, Benjamin and Diamond, Joshua M and Goldberg, Hilary J and Courtwright, Andrew M},
  title = {The Impact of Prelung Transplant HLA Antibodies on Post-transplant Outcomes in Recipients With Autoimmune Lung Disease},
  journal = {Transplantation Proceedings},
  year = {2024},
  doi = {10.1016/j.transproceed.2024.06.006}
}
Kostenlos starten →